Distribution of GFI136N in AML patients and healthy control patients
| Population . | AA . | GA . | GG . | Frequency allele A . | OR . | P* . | 95% CI . |
|---|---|---|---|---|---|---|---|
| German and Dutch patients and control patients | |||||||
| Patients | 1 | 195 | 1610 | 0.054 ± 0.005 | 1.6 | < 8 × 10−5 | 1.3-2 |
| Control patients | 1 | 118 | 1572 | 0.035 ± 0.003 | |||
| Patients by location | |||||||
| Germany patients | 1 | 134 | 1129 | 0.053 ± 0.004 | 1.6 | < 2 × 10−3 | 1.2-2 |
| Germany control patients | 1 | 87 | 1162 | 0.035 ± 0.004 | |||
| The Netherlands patients | 0 | 61 | 481 | 0.056 ± 0.007 | 1.6 | .02 | 1.1-2.6 |
| The Netherlands control patients | 0 | 31 | 410 | 0.035 ± 0.006 | |||
| According to smoking status† | |||||||
| Smokers AML | 0 | 9 | 39 | 0.09 ± 0.028 | 3.4 | .04 | 1.1-11.8 |
| Smokers control patients | 0 | 4 | 59 | 0.03 ± 0.015 | |||
| Nonsmokers AML | 0 | 13 | 41 | 0.12 ± 0.016 | 4.3 | .003 | 1.5-12.2 |
| Nonsmokers control patients | 0 | 6 | 82 | 0.03 ± 0.013 |
| Population . | AA . | GA . | GG . | Frequency allele A . | OR . | P* . | 95% CI . |
|---|---|---|---|---|---|---|---|
| German and Dutch patients and control patients | |||||||
| Patients | 1 | 195 | 1610 | 0.054 ± 0.005 | 1.6 | < 8 × 10−5 | 1.3-2 |
| Control patients | 1 | 118 | 1572 | 0.035 ± 0.003 | |||
| Patients by location | |||||||
| Germany patients | 1 | 134 | 1129 | 0.053 ± 0.004 | 1.6 | < 2 × 10−3 | 1.2-2 |
| Germany control patients | 1 | 87 | 1162 | 0.035 ± 0.004 | |||
| The Netherlands patients | 0 | 61 | 481 | 0.056 ± 0.007 | 1.6 | .02 | 1.1-2.6 |
| The Netherlands control patients | 0 | 31 | 410 | 0.035 ± 0.006 | |||
| According to smoking status† | |||||||
| Smokers AML | 0 | 9 | 39 | 0.09 ± 0.028 | 3.4 | .04 | 1.1-11.8 |
| Smokers control patients | 0 | 4 | 59 | 0.03 ± 0.015 | |||
| Nonsmokers AML | 0 | 13 | 41 | 0.12 ± 0.016 | 4.3 | .003 | 1.5-12.2 |
| Nonsmokers control patients | 0 | 6 | 82 | 0.03 ± 0.013 |
Allele frequencies for the GFI136N variant among white AML patients and control patients in Germany and in The Netherlands. GFI136N was enriched 1.6-fold in AML patients (P < 8 × 10−5) compared with the control population, which was confirmed after adjusting for age and sex.
AML indicates acute myeloid leukemia; CI, confidence interval; GFI1, Growth Factor Independence 1; and OR, odds ratio.
The Hardy-Weinberg equilibrium was tested and fit expectation with the exception that the frequency of genotype AA was lower than expected (1 vs 5; P = .01).
With reference to Essen and Marburg.